Bottom Line: Manufacturers stall their federal growth by treating specialized government health care system the same as standard commercial accounts, effectively ensuring their clinical value remains misaligned with the fundamental mission of the agencies. In commercial markets, manufacturers compete through pricing strategies, contracting leverage, and incremental clinical differentiation. Success in these sectors is measured as frequently as by quarterly shifts in market sh

Bottom Line: The VA’s Standardized National Baseline mandate consolidates clinical authority, forcing vendors to square their offerings with a singular operational structure and shift field tactics accordingly. The VA's Standardized National Baseline (SNB) is a transformative initiative poised to redefine how the VA operates and, consequently, how pharmaceutical and medical device manufacturers will need to engage with this health system. This structural shift forces a massiv

Bottom Line: In a rapidly evolving federal healthcare environment, manufacturer success in 2026 hinges on an organization’s ability to execute against five critical catalysts that are currently reshaping the market landscape. The federal healthcare landscape - encompassing the Department of Veterans Affairs (VA) and the Department of Defense (DoD) - is entering a period of significant structural transition. Several regulatory and administrative events will change how manufact